VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
VTAE was delisted on the 24th of October, 2016.
98 hedge funds and large institutions have $507M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2016 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 20 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
135% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 20
123% more capital invested
Capital invested by funds: $227M → $507M (+$280M)
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
38% more funds holding
Funds holding: 71 → 98 (+27)
42% less call options, than puts
Call options by funds: $1.4M | Put options by funds: $2.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$20.6M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
+$15.5M |
| 3 |
TAL
TIG Advisors LLC
New York
|
+$14.9M |
| 4 |
WIC
Water Island Capital
New York
|
+$14.5M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$36.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.9M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$8.21M |
VTAE Hedge Fund Activity: Q3 2016 in Review
98 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q3 2016, worth a combined $507M — up 123% from $227M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new VTAE positions and 20 closed out — a net gain of 27 holders — while 26 added to existing stakes and 18 trimmed.
The largest buyer was Alpine Associates Management, opening a new position worth an estimated $20.6M. The largest seller was Fidelity Investments, cutting an estimated $39.8M.
- 98 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q3 2016, up from 71 in Q2 2016.
- Funds reported $507M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q3 2016, up 123% quarter-over-quarter.
- 47 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q3 2016 and 20 closed out, a net change of +27 holders.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q3 2016 was Alpine Associates Management, an estimated $20.6M added.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q3 2016 was Fidelity Investments, an estimated $39.8M sold.
Based on aggregated 13F filings for Q3 2016.